An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients…
The efficacy of immune checkpoint inhibitors has been shown to depend on preexisting antitumor immunity; thus, their combination with cancer vaccines is an attractive therapeutic approach. Plasmacytoid dendritic cells (PDC) are strong inducers of antitumor responses and represent promising vaccine candidates.
- Ref: doi: 10.1080/2162402X.2020.1738812
- Année de publication : 2020
- Auteurs : Charles J, Chaperot L, Hannani D, Bruder Costa J, Templier I, Trabelsi S, Gil H, Moisan A, Persoons V, Hegelhofer H, Schir E, Quesada JL, Aspord C, Manches O, Coulie PG, Khammari A, Dreno B, Leccia MT, Plumas J.
- Réseaux : Réseaux: « Immunothérapies »